Minireview: MIRomics in Endocrinology: A Novel Approach for Modeling Endocrine Diseases

由 Szabó, Péter M., Butz, Henriett, Igaz, Péter, Rácz, Károly, Hunyady, László, Patócs, Attila
發表在 Mol Endocrinol (2013)

miRNA-target network reveals miR-124as a key miRNA contributing to clear cell renal cell carcinoma aggressive behaviour by targeting CAV1 and FLOT1

由 Butz, Henriett, Szabó, Peter M., Khella, Heba W.Z., Nofech-Mozes, Roy, Patocs, Attila, Yousef, George M.
發表在 Oncotarget (2015)

Integrative analysis of neuroblastoma and pheochromocytoma genomics data

由 Szabó, Peter M, Pintér, Miklós, Szabó, Diana Rita, Zsippai, Adrienn, Patócs, Attila, Falus, András, Rácz, Károly, Igaz, Peter
出版 2012

mRNA and microRNA expression patterns in adrenocortical cancer

由 Zsippai, Adrienn, Szabó, Diana Rita, Szabó, Peter M, Tömböl, Zsófia, Bendes, Melinda R, Nagy, Zoltán, Rácz, Károly, Igaz, Peter
出版 2011

Nivolumab in Patients with Advanced Platinum-Resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275

由 Galsky, Matthew D., Saci, Abdel, Szabo, Peter M., Han, G. Celine, Grossfeld, Gary, Collette, Sandra, Siefker-Radtke, Arlene, Necchi, Andrea, Sharma, Padmanee
發表在 Clin Cancer Res (2020)

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC

由 Ross-Macdonald, Petra, Walsh, Alice M, Chasalow, Scott D, Ammar, Ron, Papillon-Cavanagh, Simon, Szabo, Peter M, Choueiri, Toni K, Sznol, Mario, Wind-Rotolo, Megan
發表在 J Immunother Cancer (2021)

Neighbours of cancer-related proteins have key influence on pathogenesis and could increase the drug target space for anticancer therapies

由 Módos, Dezső, Bulusu, Krishna C., Fazekas, Dávid, Kubisch, János, Brooks, Johanne, Marczell, István, Szabó, Péter M., Vellai, Tibor, Csermely, Péter, Lenti, Katalin, Bender, Andreas, Korcsmáros, Tamás
發表在 NPJ Syst Biol Appl (2017)

Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer

由 Wang, Li, Gong, Yixuan, Saci, Abdel, Szabo, Peter M., Martini, Alberto, Necchi, Andrea, Siefker-Radtke, Arlene, Pal, Sumanta, Plimack, Elizabeth R., Sfakianos, John P., Bhardwaj, Nina, Horowitz, Amir, Farkas, Adam M., Mulholland, David, Fischer, Bruce S., Oh, William K., Sharma, Padmanee, Zhu, Jun, Galsky, Matthew D.
發表在 Eur Urol (2019)

Multiple SARS-CoV-2 Introductions Shaped the Early Outbreak in Central Eastern Europe: Comparing Hungarian Data to a Worldwide Sequence Data-Matrix

由 Kemenesi, Gábor, Zeghbib, Safia, Somogyi, Balázs A, Tóth, Gábor Endre, Bányai, Krisztián, Solymosi, Norbert, Szabo, Peter M, Szabó, István, Bálint, Ádám, Urbán, Péter, Herczeg, Róbert, Gyenesei, Attila, Nagy, Ágnes, Pereszlényi, Csaba István, Babinszky, Gergely Csaba, Dudás, Gábor, Terhes, Gabriella, Zöldi, Viktor, Lovas, Róbert, Tenczer, Szabolcs, Kornya, László, Jakab, Ferenc
發表在 Viruses (2020)

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer

由 Wang, Li, Saci, Abdel, Szabo, Peter M., Chasalow, Scott D., Castillo-Martin, Mireia, Domingo-Domenech, Josep, Siefker-Radtke, Arlene, Sharma, Padmanee, Sfakianos, John P., Gong, Yixuan, Dominguez-Andres, Ana, Oh, William K., Mulholland, David, Azrilevich, Alex, Hu, Liangyuan, Cordon-Cardo, Carlos, Salmon, Hélène, Bhardwaj, Nina, Zhu, Jun, Galsky, Matthew D.
發表在 Nat Commun (2018)

Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer

由 Kummar, Shivaani, Oza, Amit M., Fleming, Gini F., Sullivan, Daniel M., Gandara, David R., Naughton, Michael J., Villalona-Calero, Miguel A., Morgan, Robert J., Szabo, Peter M., Youn, Ahrim, Chen, Alice P., Ji, Jiuping, Allen, Deborah E., Lih, Chih-Jian, Mehaffey, Michele G., Walsh, William D., McGregor, Paul M., Steinberg, Seth M., Williams, Paul M., Kinders, Robert J., Conley, Barbara A., Simon, Richard M., Doroshow, James H.
發表在 Clin Cancer Res (2015)

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

由 Skoulidis, Ferdinandos, Goldberg, Michael E., Greenawalt, Danielle M., Hellmann, Matthew D., Awad, Mark M., Gainor, Justin F., Schrock, Alexa B., Hartmaier, Ryan J., Trabucco, Sally E., Gay, Laurie, Ali, Siraj M., Elvin, Julia A., Singal, Gaurav, Ross, Jeffrey S., Fabrizio, David, Szabo, Peter M., Chang, Han, Sasson, Ariella, Srinivasan, Sujaya, Kirov, Stefan, Szustakowski, Joseph, Vitazka, Patrik, Edwards, Robin, Bufill, Jose A., Sharma, Neelesh, Ou, Sai-Hong I., Peled, Nir, Spigel, David R., Rizvi, Hira, Aguilar, Elizabeth Jimenez, Carter, Brett W., Erasmus, Jeremy, Halpenny, Darragh F., Plodkowski, Andrew J., Long, Niamh M., Nishino, Mizuki, Denning, Warren L., Galan-Cobo, Ana, Hamdi, Haifa, Hirz, Taghreed, Tong, Pan, Wang, Jing, Rodriguez-Canales, Jaime, Villalobos, Pamela A., Parra, Edwin R., Kalhor, Neda, Sholl, Lynette M., Sauter, Jennifer L., Jungbluth, Achim A., Mino-Kenudson, Mari, Azimi, Roxana, Elamin, Yasir Y., Zhang, Jianjun, Leonardi, Giulia C., Jiang, Fei, Wong, Kwok-Kin, Lee, J. Jack, Papadimitrakopoulou, Vassiliki A., Wistuba, Ignacio I., Miller, Vincent A., Frampton, Garrett M., Wolchok, Jedd D., Shaw, Alice T., Jänne, Pasi A., Stephens, Philip J., Rudin, Charles M., Geese, William J., Albacker, Lee A., Heymach, John V.
發表在 Cancer Discov (2018)